Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$146 Mln
P/E Ratio
--
P/B Ratio
0.85
Industry P/E
--
Debt to Equity
0.02
ROE
-0.34 %
ROCE
-33.34 %
Div. Yield
0 %
Book Value
4.17
EPS
-1.59
CFO
CHF-160.45 Mln
EBITDA
CHF-163.54 Mln
Net Profit
CHF-190.48 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Molecular Partners AG (MOLN)
| -13.23 | 4.83 | -22.67 | 6.19 | -37.87 | -28.37 | -17.44 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Molecular Partners AG (MOLN)
| 13.47 | -36.18 | -65.85 | -7.55 | 18.44 | -8.04 | -27.53 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1... clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Address: Wagistrasse 14, Schlieren, Switzerland, 8952 Read more
Co-Founder, CEO, Member of Management Board & Director
Dr. Patrick Amstutz Ph.D.
Co-Founder, CEO, Member of Management Board & Director
Dr. Patrick Amstutz Ph.D.
Headquarters
Schlieren
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Molecular Partners AG (MOLN) stood at $ 159 Mln as on 31-Dec-24
The share price of Molecular Partners AG (MOLN) is $4.12 (NASDAQ) as of 23-Apr-2025 10:46 EDT. Molecular Partners AG (MOLN) has given a return of -37.87% in the last 3 years.
Molecular Partners AG (MOLN) has a market capitalisation of $ 146 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Molecular Partners AG (MOLN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Molecular Partners AG (MOLN) and enter the required number of quantities and click on buy to purchase the shares of Molecular Partners AG (MOLN).
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Address: Wagistrasse 14, Schlieren, Switzerland, 8952
The CEO & director of Dr. Patrick Amstutz Ph.D.. is Molecular Partners AG (MOLN), and CFO & Sr. VP is Dr. Patrick Amstutz Ph.D..
There is no promoter pledging in Molecular Partners AG (MOLN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Molecular Partners AG (MOLN) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.98
|
|
Operating margin(%)
|
-1086.84
|
|
Net Margin(%)
|
-1087.38
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Molecular Partners AG (MOLN) was $0 Mln.
$0.24
(
